DelveInsight’s Colorectal Cancer pipeline report provides a comprehensive insight into the Colorectal Cancer drug profiles, including clinical and non-clinical stage products. The report also includes Colorectal Cancer therapeutics assessment by product type, route of administration, and molecule type.
Some of the Key Highlights from the Colorectal Cancer Pipeline Report
-
The Colorectal Cancer pipeline comprises emerging therapies in the different clinical stages, including MRTX849, Tucatinib, PolyPEPI 1018, CYAD 101, and others.
-
Key players working to improve the Colorectal Cancer treatment landscape include Mirati Therapeutics, Seagen, Treos Bio, Celyad Oncology, among others.
-
The Colorectal Cancer therapies in the late stage of development include MRTX849 (Mirati Therapeutics) and others.
-
CYAD 101 is being developed and investigated in the phase I Colorectal Cancer clinical trials by Celyad Oncology.
Request for the sample to know more about the colorectal cancer pipeline @ Colorectal Cancer Pipeline Analysis
Colorectal Cancer Overview
Colorectal Cancer, also known as bowel cancer, colon cancer, or rectal cancer, is any colon or rectum cancer. When tumours form in the lining of the large intestine, colorectal cancer develops. It affects both men and women equally. After the age of 50, the risk of developing colorectal cancer increases.
Colorectal Cancer Symptoms
The most common Colorectal Cancer symptoms are:
-
The shift in bowel habits
-
Blood in the stool.
-
Bright red blood spotting in the rectum
-
Cramping or pain in the abdomen
-
Tiredness and unexplained weight loss
-
Vomiting or nausea
Colorectal Cancer Treatment
The goal of Colorectal Cancer treatment is usually to prolong life and relieve or prevent symptoms. Treatment for colon cancer that has spread to other organs frequently necessitates a combination of treatments. Surgery, chemotherapy, image-guided therapies such as MRI and CT, radiation therapy, targeted therapies, and immunotherapy are examples of such treatments. Polyps cause the majority of colorectal cancers. The removal of colon polyps can help prevent colorectal cancer. The most common medical treatment for colorectal cancer is surgery.
Colorectal Cancer Pipeline Analysis: Drug Profiles
MRTX849: Mirati Therapeutics
Product Description
MRTX849 (Adagrasib) is an investigational, highly selective and potent oral small-molecule therapy that is being developed to shrink difficult-to-treat cancers with the KRASG12C mutation. The drug is currently being tested in Phase III clinical trials to treat colorectal cancer and non-small cell lung cancer.
Phase III
NCT04793958: Mirati Therapeutics began a randomised Phase III study of MRTX849 in combination with cetuximab versus chemotherapy in patients with advanced colorectal cancer with KRAS G12C mutation and disease progression on or after standard first-line therapy in March 2021.
Colorectal Cancer Pipeline Therapies and Key Companies
-
MRTX849: Mirati Therapeutics
-
Tucatinib: Seagen
-
PolyPEPI 1018: Treos Bio
-
CYAD 101: Celyad Oncology
Find out more about the emerging drugs @ Colorectal Cancer Clinical Trials
Colorectal Cancer Assessment
-
By Product Type
-
Monotherapy
-
Combination Therapy
-
By Stage
-
Discovery
-
Pre-Clinical
-
Phase I
-
Phase II
-
Phase III
-
Pre-registration
-
By Route of Administration
-
Inhalation
-
Intravenous
-
Oral
-
Subcutaneous
-
By Molecule Type
-
Small Molecule
-
Stem Cell Therapy
-
Gene Therapy
-
Targets
-
Immune System
-
Multiple Kinase
-
By Mechanism of Action
-
Protease Inhibitors
-
Immunomodulatory
Scope of the Report
Coverage: Global
Colorectal Cancer Key Players: Mirati Therapeutics, Seagen, Treos Bio, Celyad Oncology, among others
Colorectal Cancer Pipeline Therapies: MRTX849, Tucatinib, PolyPEPI 1018, CYAD 101, and others
Table of Contents
|
1. |
Introduction |
|
2. |
Executive Summary |
|
3. |
Colorectal Cancer: Overview |
|
4. |
Colorectal Cancer Pipeline Therapeutics |
|
5. |
Colorectal Cancer Late Stage Products (Pre-registration) |
|
6. |
Colorectal Cancer Late Stage Products (Phase III) |
|
7. |
Colorectal Cancer Mid Stage Products (Phase II) |
|
8. |
Colorectal Cancer Early Stage Products (Phase I) |
|
9. |
Colorectal Cancer Pre-clinical and Discovery Stage Products |
|
10. |
Colorectal Cancer Therapeutic Assessment |
|
11. |
Colorectal Cancer Inactive Products |
|
12. |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13. |
Colorectal Cancer- Unmet Needs |
|
14. |
Colorectal Cancer- Market Drivers and Barriers |
|
15. |
Appendix |
|
16. |
About DelveInsight |
Get in touch with our business executive for Healthcare Due Diligence Services
Key questions answered in the Colorectal Cancer Pipeline Report
-
What Colorectal Cancer Treatments are available?
-
How many pharmaceutical companies are working on treatments for colorectal cancer?
-
Which of these companies’ pharmaceuticals is the most commonly used?
-
How many Colorectal Cancer medications are manufactured by each company?
-
How many colorectal cancer drugs are in the early, mid, or late stages of development?
-
How many of the currently being developed therapies can be used alone or in combination with other treatments?
-
What are the critical Colorectal Cancer collaborations, mergers and acquisitions, and licencing practises?
Related Reports
Metastatic Colorectal Cancer Pipeline Insights
Get a comprehensive analysis of Metastatic Colorectal Cancer pipeline therapies and key companies, including G1 Therapeutics, Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Celyad Oncology SA, Menarini Group, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/